𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma

✍ Scribed by Robert J. Amato; Margaret Morgan; Anish Rawat

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
97 KB
Volume
106
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A pilot study of thalidomide in patients
A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma
✍ Danai D. Daliani; Christos N. Papandreou; Peter F. Thall; Xuemei Wang; Cherie Pe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 96 KB 👁 2 views

## Background: The highly vascular nature of renal cell carcinoma (rcc) suggests that angiogenesis inhibition may be therapeutic for patients with this disease. thalidomide inhibits basic fibroblast growth factor and vascular endothelial growth factor (vegf)-induced angiogenesis. ## Methods: In a

A Phase II study of irinotecan in patien
A Phase II study of irinotecan in patients with advanced renal cell carcinoma
✍ Karim Fizazi; Frédéric Rolland; Christine Chevreau; Jean-Pierre Droz; Dominique 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 1 views

## Abstract ## BACKGROUND Patients with disseminated renal cell carcinoma (RCC) have a poor outcome, and the disease is considered highly resistant to chemotherapy. Irinotecan is an active drug in the treatment of a number of neoplastic diseases and is not concerned with the multidrug‐resistance p

Phase 2 trial of talactoferrin in previo
Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
✍ Eric Jonasch; Walter M. Stadler; Ronald M. Bukowski; Teresa G. Hayes; Atul Varad 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 1 views

## Abstract ## BACKGROUND. Talactoferrin (TLF), a recombinant form of human lactoferrin (hLF), is an immunomodulatory iron‐binding glycoprotein first identified in breast milk. Its immunomodulatory functions include activation of natural killer (NK) and lymphokine‐activated killer cells and enhanc

A Phase II trial of intravenous gemcitab
A Phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-α in patients with metastatic renal cell carcinoma
✍ Christopher W. Ryan; Nicholas J. Vogelzang; Walter M. Stadler 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB 👁 1 views

## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuous‐infusion 5‐fluorouracil (5‐FU) in combination with subcutaneous interleukin‐2 (IL2) and interferon‐α (IFNA) in patients with metastatic renal cell carcinoma. ## METH